Key result
High expression of lncRNA EPB41L4A-AS1 was associated with poor prognosis and metastasis in colorectal cancer, and its knockdown inhibited tumor cell proliferation and invasion in vitro.
Why the study?
Colorectal cancer is a common malignancy with increasing incidence, and accumulating evidence indicates that long noncoding RNAs play important roles in tumorigenesis.
lncRNA EPB41L4A-AS1 promotes colorectal cancer progression via the Rho/ROCK pathway and may serve as a novel biomarker and therapeutic target.
EPB41L4A-AS1 expression may inform colorectal cancer prognosis; leaves open its therapeutic targeting pending clinical validation.
Colorectal cancer (CRC) is one of the most common malignant tumors worldwide. In terms of cancer-related death, colon cancer ranks second and third among men and women, respectively, and the incidence is increasing annually. Accumulating evidence have indicated that long noncoding RNA (lncRNA) plays an important role in tumorigenesis. In this study, we found that lncRNA EPB41L4A-AS1 was highly expressed in CRC tissues and was associated with poor prognosis and tumor metastasis in patients with CRC. In vitro studies showed that the knockdown of EPB41L4A-AS1 inhibited the proliferation, migration, invasion, and epithelial-mesenchymal transition of CRC cells. Mechanically, we found that EPB41L4A-AS1 may participate in the development of CRC by activating the Rho/Rho-associated protein kinase signaling pathway. Collectively, these results demonstrated that EPB41L4A-AS1 can promote the proliferation, invasion, and migration of CRC, and it may be a novel biomarker for the diagnosis and targeted treatment of CRC.
No takes yet. Share an insight, caveat, or question.
Bin et al. (2020) studied Colorectal cancer. lncRNA EPB41L4A-AS1 was evaluated on Prognosis, tumor metastasis, and in vitro cell proliferation, migration, invasion, and epithelial-mesenchymal transition. High expression of lncRNA EPB41L4A-AS1 was associated with poor prognosis and metastasis in colorectal cancer, and its knockdown inhibited tumor cell proliferation and invasion in vitro.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: